Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21185626 | 0.78 | PDGFRB (0.52) | PDGFRAPDGFRBSRCTGFBR1MET | |
| SCHEMBL22704094 | 0.76 | PDGFRB (0.53) | PDGFRAPDGFRBSRCTGFBR1MET | |
| SCHEMBL21358445 | 0.75 | PDGFRA (0.58) | PDGFRAPDGFRBSRCTGFBR1MET | |
| SCHEMBL21185438 | 0.74 | PDGFRB (0.51) | PDGFRAPDGFRBSRCTGFBR1MET | |
| SCHEMBL4400367 | 0.74 | PDGFRB (0.72) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL21299301 | 0.71 | PDGFRA (0.50) | PDGFRAPDGFRBSRCTGFBR1KDR | |
| SCHEMBL21185785 | 0.69 | MET (0.44) | PDGFRAPDGFRBSRCTGFBR1MET | |
| SCHEMBL17732799 | 0.68 | HTR1A (0.44) | PDGFRAMETKDRAURKATEK | |
| SCHEMBL15309998 | 0.68 | SRC (0.53) | PDGFRAPDGFRBSRCTGFBR1MET | |
| SCHEMBL23923068 | 0.67 | PDGFRA (0.69) | PDGFRAPDGFRBMETKDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11124481-B2 | Method of preparing fluorine-18 labeled Cabozantinib and its analogs | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124481-B2 | Method of preparing fluorine-18 labeled Cabozantinib and its analogs | FGFR1, PDGFRA, KIF18B | PDGFRA 2/4885PDGFRB 9/4885SRC 1000/4885 |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRA 3965/4885PDGFRB 3177/4885SRC 4248/4885 |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | FGFR1, PDGFRA, KIF18B | PDGFRA 2/4885PDGFRB 9/4885SRC 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.